These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16774855)

  • 1. Regarding the article "Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions", by Feeley et al.
    Friedlaender GE
    Bone; 2006 Sep; 39(3):666; author reply 667. PubMed ID: 16774855
    [No Abstract]   [Full Text] [Related]  

  • 2. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
    Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
    Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
    J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
    Ye L; Lewis-Russell JM; Kynaston H; Jiang WG
    J Urol; 2007 Sep; 178(3 Pt 1):1086-91. PubMed ID: 17644136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
    Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
    Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
    Haudenschild DR; Palmer SM; Moseley TA; You Z; Reddi AH
    Cancer Res; 2004 Nov; 64(22):8276-84. PubMed ID: 15548695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.
    Schwaninger R; Rentsch CA; Wetterwald A; van der Horst G; van Bezooijen RL; van der Pluijm G; Löwik CW; Ackermann K; Pyerin W; Hamdy FC; Thalmann GN; Cecchini MG
    Am J Pathol; 2007 Jan; 170(1):160-75. PubMed ID: 17200191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
    Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway.
    Katsuno Y; Hanyu A; Kanda H; Ishikawa Y; Akiyama F; Iwase T; Ogata E; Ehata S; Miyazono K; Imamura T
    Oncogene; 2008 Oct; 27(49):6322-33. PubMed ID: 18663362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
    Ye L; Kynaston H; Jiang WG
    Mol Cancer Res; 2008 Oct; 6(10):1594-606. PubMed ID: 18922975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer.
    Miwa S; Mizokami A; Keller ET; Taichman R; Zhang J; Namiki M
    Cancer Res; 2005 Oct; 65(19):8818-25. PubMed ID: 16204052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer.
    Bobinac D; Marić I; Zoricić S; Spanjol J; Dordević G; Mustać E; Fuckar Z
    Croat Med J; 2005 Jun; 46(3):389-96. PubMed ID: 15861517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone metastasis in prostate cancer: molecular and cellular mechanisms (Review).
    Ye L; Kynaston HG; Jiang WG
    Int J Mol Med; 2007 Jul; 20(1):103-11. PubMed ID: 17549396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct evidence that PTHrP expression promotes prostate cancer progression in bone.
    Deftos LJ; Barken I; Burton DW; Hoffman RM; Geller J
    Biochem Biophys Res Commun; 2005 Feb; 327(2):468-72. PubMed ID: 15629138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway.
    Kodach LL; Bleuming SA; Peppelenbosch MP; Hommes DW; van den Brink GR; Hardwick JC
    Gastroenterology; 2007 Oct; 133(4):1272-81. PubMed ID: 17919499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.
    Pham LK; Liang M; Adisetiyo HA; Liao CP; Cohen MB; Tahara SM; Frenkel B; Kasahara N; Roy-Burman P
    Endocr Relat Cancer; 2013 Dec; 20(6):861-74. PubMed ID: 24042462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.
    Feeley BT; Liu NQ; Conduah AH; Krenek L; Roth K; Dougall WC; Huard J; Dubinett S; Lieberman JR
    J Bone Miner Res; 2006 Oct; 21(10):1571-80. PubMed ID: 16995812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss.
    Wakchoure S; Swain TM; Hentunen TA; Bauskin AR; Brown DA; Breit SN; Vuopala KS; Harris KW; Selander KS
    Prostate; 2009 May; 69(6):652-61. PubMed ID: 19152406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of Shh and BMP paracrine signaling in a prostate cancer xenograft.
    Shaw A; Gipp J; Bushman W
    Differentiation; 2010 Jan; 79(1):41-7. PubMed ID: 19773112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins.
    Lai TH; Fong YC; Fu WM; Yang RS; Tang CH
    Prostate; 2008 Sep; 68(12):1341-53. PubMed ID: 18512729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.